FLT3LG and neoplasm: While pre-clinical studies demonstrated improved tumor control when combining anti-PD-L1 blockade with administration of Flt3L as the main growth factor for DCs, administration of recombinant Flt3L as a monotherapy failed to show efficacy in patients with advanced malignancies.